Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 USD | +6.45% | +1.60% | -20.57% |
Apr. 29 | Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem | CI |
Mar. 28 | Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.57% | 25.66M | |
+20.79% | 47.9B | |
+46.56% | 41.42B | |
-2.61% | 40.7B | |
-6.20% | 28.92B | |
+10.21% | 25.55B | |
-21.83% | 19.27B | |
-2.00% | 12.15B | |
+30.77% | 12.14B | |
-0.82% | 11.99B |
- Stock Market
- Equities
- ITRM Stock
- News Iterum Therapeutics plc
- HC Wainwright Upgrades Iterum Therapeutics to Buy From Neutral, Price Target is $6